BIOMAT Database Logo BIOMAT Database Logo

Immunity to poliovirus and immunization with inactivated poliovirus vaccine after autologous bone marrow transplantation. 1994

K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Department of Infectious Diseases, Uppsala University, Sweden.

Titers of antibody to poliovirus in 102 patients were determined with a sensitive neutralization assay before and 1 year after autologous bone marrow transplantation. At 1 year 14 patients (14%) had lost antibodies to poliovirus type 1 (P < .001), 10 (10%) to poliovirus type 2 (P < .05), and 13 (13%) to poliovirus type 3 (P < .01). Twenty-two patients had lost antibodies to at least one type of poliovirus. Follow-up of unimmunized patients 2 years (n = 40) and 3 years (n = 23) after transplantation documented a continuous decrease in antibody titer; by 3 years after transplantation, another 6 patients had become seronegative. When one dose of inactivated trivalent poliovirus vaccine was administered 1 year after transplantation, 2 (25%) of 8 patients seronegative for poliovirus type 1 had an increase of at least fourfold in antibody titer; after three doses, 10 (83%) of 12 patients exhibited such an increase (P < .05). The corresponding figures were 5 (71%) of 7 and 13 (100%) of 13 for poliovirus type 2 (difference not significantly) and 2 (22%) of 9 and 14 (88%) of 16 for poliovirus type 3 (P < .01). These results indicate that at least 30% of patients undergoing autologous bone marrow transplantation including those seronegative for poliovirus before transplantation will benefit from reimmunization with three doses of inactivated trivalent poliovirus vaccine 1 year after transplantation.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007115 Immunization Schedule Schedule giving optimum times usually for primary and/or secondary immunization. Immunization Schedules,Schedule, Immunization,Schedules, Immunization
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007156 Immunologic Memory The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus. Immune Memory,Immunological Memory,Memory, Immunologic,Immune Memories,Immunologic Memories,Immunological Memories,Memory, Immune,Memory, Immunological
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011054 Poliovirus Vaccine, Inactivated A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS. Salk Vaccine,Inactivated Poliovirus Vaccine,Vaccine, Inactivated Poliovirus,Vaccine, Salk
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children

Related Publications

K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization.
December 1991, The Pediatric infectious disease journal,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
June 1992, Bone marrow transplantation,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine.
November 1993, The Journal of infectious diseases,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
[Post-vaccination immunity after allogenic and autologous bone marrow transplantation].
May 1999, Casopis lekaru ceskych,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Early immunization with inactivated poliovirus vaccine in premature infants.
July 1995, The Journal of pediatrics,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Boosting of Mucosal Immunity After Fractional-Dose Inactivated Poliovirus Vaccine.
November 2018, The Journal of infectious diseases,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Intestinal immunity induced by inactivated poliovirus vaccine.
June 1987, Vaccine,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation.
May 1988, Blood,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
Neutralising antibody response to oral poliovirus vaccine after primary immunisation with inactivated poliovirus vaccine.
November 1998, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
K Pauksen, and V Hammarström, and P Ljungman, and J Sjölin, and G Oberg, and G Lönnerholm, and L Magnius, and B Simonsson
[Kinetics of vaccine antibodies to tetanus toxoid, diphtheria toxoid, measles virus, poliomyelitis virus and pneumococci after allogenic and autologous bone marrow transplantation and booster immunization. 1: The kinetics of vaccine antibodies to tetanus toxoid after allogenic and autologous bone marrow transplantation].
June 1992, Kinderarztliche Praxis,
Copied contents to your clipboard!